A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
The tele-icu services which had a soft launch four months ago have already provided valuable assistance to 250+ patients in some of the remotest villages in India
The emergence of new infections in India is a growing concern
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Subscribe To Our Newsletter & Stay Updated
